SCHEMBL1685242

SCHEMBL1685242

O=c1cc(-c2ccc(Nc3ccc(N4CCC(N5CCC(O)CC5)CC4)cc3)c3nccn23)cc[nH]1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 9/20 0.55
SYK P43405 3/20 0.40
MAP4K1 Q92918 5/20 0.38
ROCK2 O75116 1/20 0.37
FGFR1 P11362 1/20 0.36
CDK4 P11802 1/20 0.36
CCNA2 P20248 1/20 0.36
FGFR2 P21802 1/20 0.36
FGFR4 P22455 1/20 0.36
FGFR3 P22607 1/20 0.36
CCND1 P24385 1/20 0.36
CDK2 P24941 1/20 0.36
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10133942 0.93 MAPKAPK5 (0.57) MAPKAPK5SYKROCK2CDK4CCNA2
SCHEMBL1685116 0.93 MAPKAPK5 (0.56) MAPKAPK5SYKROCK2
SCHEMBL10134493 0.92 MAPKAPK5 (0.60) MAPKAPK5SYKROCK2
SCHEMBL10134462 0.90 MAPKAPK5 (0.58) MAPKAPK5SYKROCK2CDK4CCND1
SCHEMBL10134496 0.89 MAPKAPK5 (0.57) MAPKAPK5SYKROCK2FGFR1CDK4
SCHEMBL1685134 0.88 MAPKAPK5 (0.63) MAPKAPK5SYKROCK2
SCHEMBL1685185 0.87 MAPKAPK5 (0.54) MAPKAPK5SYKROCK2FGFR1CDK4
SCHEMBL1685208 0.86 MAPKAPK5 (0.64) MAPKAPK5SYKROCK2
SCHEMBL14162720 0.85 MAPKAPK5 (0.63) MAPKAPK5SYKROCK2CDK4CCNA2
SCHEMBL1792719 0.85 MAPKAPK5 (0.54) MAPKAPK5SYKROCK2FGFR1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885SYK 1605/4885MAP4K1 86/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885SYK 1605/4885MAP4K1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.